Telehealth Weight Loss
3 articles on Telehealth Weight Loss, written by Shotlee and medically reviewed for clinical accuracy.
Hims & Hers Stock: Costly Wegovy Deal Challenges
Hims & Hers has resolved its dispute with Novo Nordisk, shifting to official weight loss drugs like Wegovy over controversial compounded GLP-1 alternatives. This brings legal clarity but slams profitability with higher costs and a cautious Q1 2026 revenue outlook of $600-625 million. With 2.5 million subscribers, can the stock rebound amid debt and investigations?
4 min read
Hims & Hers GLP-1 Pill Launch Backfires, Fuels Compounder Crackdown
Hims & Hers aimed to disrupt the GLP-1 market with a cheap oral semaglutide pill, but faced swift FDA backlash and a patent lawsuit from Novo Nordisk. The retreat highlights regulatory risks for compounders as branded supplies stabilize. This analysis reveals challenges in oral GLP-1 production and future paths for telehealth weight loss offerings.
6 min read
Hims & Hers Shares Sink 16% as FDA Halts Wegovy Copycat Pill
Hims & Hers Health Inc. (HIMS) has halted sales of its copycat Wegovy weight loss pill just two days after launch, leading to a 16% plunge in shares amid FDA warnings and Novo Nordisk threats. This marks a regulatory pivot as GLP-1 shortages ease. Patients and investors should note the growing scrutiny on compounded versions of popular drugs like Wegovy.
5 min read